CADTH | Search

Current Filters

Showing 41 - 50 results of 3551

Indacaterol glycopyrronium mometasone furoate (Enerzair Breezhaler) (Last Updated: Jan 22, 2021)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Enerzair Breezhaler
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months.

indacaterol /mometasone furoate (Atectura Breezhaler) (Last Updated: Jan 20, 2021)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Atectura Breezhaler
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease. Atectura Breezhaler should be prescribed for patients not adequately controlled on a long-term asthma control medication, such as ICS or whose disease severity clearly warrants treatment with both a LABA and an ICS.

Avastin for Cervical Cancer - Details (Avastin) (Last Updated: Apr 8, 2015)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Avastin
Manufacturer:
Hoffmann-La Roche Limited
Submission Type:
Initial

Zelboraf for Advanced Melanoma - Details (Zelboraf) (Last Updated: Aug 1, 2012)

CLARIFICATION: Non-disclosable information was initially used in the pCODR Clinical Guidance Report and the manufacturer requested this information be redacted until September 29, 2012 pursuant to the...
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Zelboraf
Manufacturer:
Hoffmann-La Roche Limited
Submission Type:
Initial

Treanda for Chronic Lymphocytic Leukemia (First Line) (Treanda) (Last Updated: Mar 6, 2013)

As per pCODR Procedures B5.4, the pERC deliberations for Bendamustine (Treanda) First Line treatment of patients with CLL were deferred to the January 17, 2013 pERC meeting date, once the submitter...
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Treanda
Manufacturer:
Lundbeck Canada Inc.
Submission Type:
Initial

Treanda for Chronic Lymphocytic Leukemia (Relapsed/ Refractory) (Treanda) (Last Updated: Dec 14, 2012)

As per pCODR Procedures B5.4, the pERC deliberations for Bendamustine (Treanda) First Line treatment of patients with CLL was deferred to the January 17, 2013 pERC meeting date, once the submitter...
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Treanda
Manufacturer:
Lundbeck Canada Inc.
Submission Type:
Initial
Download results as CSV